COLL
Income statement / Annual
Last year (2024), Collegium Pharmaceutical, Inc.'s total revenue was $631.45 M,
an increase of 11.41% from the previous year.
In 2024, Collegium Pharmaceutical, Inc.'s net income was $69.19 M.
See Collegium Pharmaceutical, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$631.45 M |
$566.77 M |
$463.93 M |
$276.87 M |
$310.02 M |
$296.70 M |
$280.41 M |
$28.48 M |
$1.71 M |
$0.00 |
| Cost of Revenue |
$254.11 M
|
$240.60 M
|
$254.45 M
|
$126.25 M
|
$130.18 M
|
$193.66 M
|
$165.68 M
|
$2.60 M
|
$213.00 K
|
$171.00 K
|
| Gross Profit |
$377.34 M
|
$326.17 M
|
$209.49 M
|
$150.62 M
|
$179.84 M
|
$103.04 M
|
$114.74 M
|
$25.88 M
|
$1.50 M
|
-$171.00 K
|
| Gross Profit Ratio |
0.6
|
0.58
|
0.45
|
0.54
|
0.58
|
0.35
|
0.41
|
0.91
|
0.88
|
0
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$3.98 M
|
$9.45 M
|
$9.77 M
|
$10.34 M
|
$8.66 M
|
$8.57 M
|
$14.95 M
|
$7.98 M
|
| General & Administrative Expenses |
$172.32 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$18.93 M
|
| Selling & Marketing Expenses |
$10.66 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$116.45 M
|
$126.76 M
|
$92.76 M
|
$80.63 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$182.98 M
|
$159.21 M
|
$172.19 M
|
$118.96 M
|
$113.83 M
|
$116.45 M
|
$126.76 M
|
$92.76 M
|
$80.63 M
|
$18.93 M
|
| Other Expenses |
$24.47 M
|
$0.00
|
$0.00
|
$4.58 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$94.00 K
|
$0.00
|
| Operating Expenses |
$207.45 M
|
$159.21 M
|
$176.17 M
|
$132.99 M
|
$123.60 M
|
$126.79 M
|
$135.42 M
|
$101.33 M
|
$95.58 M
|
$26.91 M
|
| Cost And Expenses |
$461.55 M
|
$399.81 M
|
$430.61 M
|
$259.24 M
|
$253.78 M
|
$320.45 M
|
$301.10 M
|
$103.92 M
|
$95.79 M
|
$26.91 M
|
| Interest Income |
$13.98 M
|
$15.62 M
|
$1.05 M
|
$12.00 K
|
$232.00 K
|
$1.94 M
|
$1.69 M
|
$582.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$73.97 M
|
$83.34 M
|
$63.21 M
|
$21.01 M
|
$28.88 M
|
$909.00 K
|
$20.13 M
|
$0.00
|
$94.00 K
|
$439.00 K
|
| Depreciation & Amortization |
$169.16 M
|
$149.26 M
|
$138.94 M
|
$68.92 M
|
$61.55 M
|
$15.48 M
|
$110.91 M
|
$594.00 K
|
$655.00 K
|
$171.00 K
|
| EBITDA |
$341.70 M |
$308.33 M |
$173.31 M |
$86.56 M |
$118.01 M |
-$6.33 M |
$91.91 M |
-$74.27 M |
-$93.43 M |
-$26.65 M |
| EBITDA Ratio |
0.54
|
0.54
|
0.37
|
0.31
|
0.38
|
-0.02
|
0.33
|
-2.61
|
-54.6
|
0
|
| Operating Income Ratio |
0.27
|
0.29
|
0.07
|
0.06
|
0.18
|
-0.08
|
-0.07
|
-2.65
|
-54.99
|
0
|
| Total Other Income/Expenses Net |
-$71.33 M
|
-$91.23 M
|
-$62.17 M
|
-$21.00 M
|
-$28.65 M
|
$1.03 M
|
-$18.44 M
|
$582.00 K
|
-$94.00 K
|
-$348.00 K
|
| Income Before Tax |
$98.57 M
|
$75.73 M
|
-$28.85 M
|
-$3.37 M
|
$27.58 M
|
-$22.72 M
|
-$39.13 M
|
-$74.87 M
|
-$94.18 M
|
-$27.26 M
|
| Income Before Tax Ratio |
0.16
|
0.13
|
-0.06
|
-0.01
|
0.09
|
-0.08
|
-0.14
|
-2.63
|
-55.04
|
0
|
| Income Tax Expense |
$29.38 M
|
$27.58 M
|
-$3.85 M
|
-$74.89 M
|
$830.00 K
|
$0.00
|
$0.00
|
$0.00
|
$94.00 K
|
-$91.00 K
|
| Net Income |
$69.19 M
|
$48.16 M
|
-$25.00 M
|
$71.52 M
|
$26.75 M
|
-$22.72 M
|
-$39.13 M
|
-$74.87 M
|
-$94.18 M
|
-$27.26 M
|
| Net Income Ratio |
0.11
|
0.08
|
-0.05
|
0.26
|
0.09
|
-0.08
|
-0.14
|
-2.63
|
-55.04
|
0
|
| EPS |
2.14 |
1.6 |
-0.74 |
2.05 |
0.78 |
-0.24 |
-1.19 |
-2.47 |
-3.88 |
-2.01 |
| EPS Diluted |
1.86 |
1.29 |
-0.74 |
1.86 |
0.76 |
-0.24 |
-1.19 |
-2.47 |
-3.88 |
-2.01 |
| Weighted Average Shares Out |
$32.27 M
|
$33.74 M
|
$33.83 M
|
$34.94 M
|
$34.41 M
|
$33.45 M
|
$32.88 M
|
$30.27 M
|
$24.26 M
|
$13.54 M
|
| Weighted Average Shares Out Diluted |
$40.42 M
|
$41.79 M
|
$33.83 M
|
$41.05 M
|
$35.15 M
|
$33.45 M
|
$32.95 M
|
$30.27 M
|
$24.26 M
|
$13.54 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
